Rob ten Hoedt Takes the Helm as Chairman at Berlin Heals Board

Berlin Heals Welcomes Rob ten Hoedt as the New Chairman of the Board

Berlin Heals Holding AG, based in Zug, Switzerland, has announced the appointment of Rob ten Hoedt as its new Chairman of the Board of Directors. This decision marks a significant milestone for the company as it gears up for an exciting year ahead. In a statement, Marko Bagaric, co-founder and member of the Board, expressed enthusiasm about ten Hoedt joining their ranks, highlighting his rich experience in global healthcare systems and medical technology.

Rob ten Hoedt's impressive 30-year career in the medical technology and healthcare sectors most recently saw him serving as Executive Vice President and President, Global Regions, at Medtronic. His leadership experience includes high-level positions at organizations like Medtronic SQDM, Vitatron, and Urologix. Ten Hoedt is well-acquainted with the demands and intricacies of medical technology, holding a degree in Commercial Economy and a Master's in Marketing. Currently, he also chairs the board for Medmix and Onward Medical, further showcasing his commitment to advancing healthcare initiatives.

In his remarks on joining Berlin Heals, ten Hoedt expressed excitement about contributing to the company's innovative therapy focused on heart failure. He stated, "Together, we will strive to bring the life-changing benefits of the C-MIC device to patients worldwide. A thrilling time lies ahead, and it is an honor to be part of it." His passion for innovation and patient care will undoubtedly play a pivotal role in shaping the company's future.

As Berlin Heals moves into a crucial year, CEO John Brumfield emphasized the importance of ten Hoedt’s knowledge and leadership experience. "We are delighted to welcome Rob ten Hoedt as our new Chairman as we enter a pivotal year for Berlin Heals," Brumfield said. His guidance will be instrumental in driving the company’s strategy and fostering growth in an increasingly competitive landscape.

Understanding C-MIC Therapy

One of the key areas of focus at Berlin Heals is the Cardiac Microcurrent (C-MIC) Therapy. This innovative treatment is delivered through a fully implantable medical device consisting of two electrodes attached to an implantable generator. This device administers direct microcurrent to the diseased heart, aiming to improve cardiac function by reducing inflammation and promoting a reversal of the heart's remodeling.

The initial generation of this therapy required a minimally invasive surgical procedure, but advancements have allowed for a new, less invasive approach. This new method can be performed in a cardiac catheterization lab and is conducive to outpatient procedures led by cardiologists, making it more accessible to patients.

Insights into Heart Failure

Heart failure is a severe condition wherein the heart struggles to supply sufficient blood to meet the body's needs. Common symptoms include fatigue, shortness of breath, and irregular heartbeats, which can severely limit one’s capacity to engage in daily activities. As a progressive disease, heart failure often leads to frequent hospital admissions and is associated with high healthcare costs. Notably, over 64 million individuals worldwide are affected by this condition, with predictions indicating that by 2050, the global financial burden of heart failure care could reach approximately $858 billion annually. Alarmingly, the condition is linked with a mortality rate that surpasses that of cancer, highlighting the urgent need for effective treatments.

About Berlin Heals Holding AG

Berlin Heals Holding AG is at the forefront of developing revolutionary treatments aimed at reversing heart failure. The company's efforts have yielded promising results following a successful First-In-Human study in 2019, which showcased long-term benefits. Recently, a Randomized Controlled Trial concluded in 2024 further solidified the effectiveness of their innovative treatments. With plans for less invasive procedures already underway, Berlin Heals is strategically positioned as a leader in heart failure treatment. With subsidiaries in Germany and the American market, the company continues to expand its reach and impact in the healthcare sector.

With Rob ten Hoedt’s leadership and a clear vision for the future, Berlin Heals is set to make significant strides in providing solutions for heart failure, enhancing patient care, and redefining treatment approaches in the medical technology arena.